Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion PharmaDHA:ORIONPHARM +0.33%72 Median PS Value is BDT20.98 as of Jul. 13, 2026, which is 100% below its 10-year median of 1.26. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.18 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 195 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 76.41% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Orion Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was BDT16.065. Orion Pharma's 10-Year median PS Ratio is 1.3059. Therefore, the Median PS Value for today is BDT20.98.
As of today (2026-07-13), Orion Pharma's share price is BDT30.10. Orion Pharma's Median PS Value is BDT20.98. Therefore, Orion Pharma's Price to Median PS Value for today is 1.47.
The historical rank and industry rank for Orion Pharma's Median PS Value or its related term are showing as below:
DHA:ORIONPHARM'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.87 Med: 1.26 Max: 2.22
Current: 1.47
During the past 12 years, the highest Price to Median PS Value of Orion Pharma was 2.22. The lowest was 0.87. And the median was 1.26.
DHA:ORIONPHARM's Price-to-Median-PS-Value is ranked worse than 76.41% of 195
companies
in the Utilities - Independent Power Producers industry
Industry Median: 1.01
vs DHA:ORIONPHARM: 1.47
Orion Pharma (DHA:ORIONPHARM) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Orion Pharma's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
30.10
/
20.98
=
1.43
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma Median PS Value Related Terms
Orion Pharma Median PS Value Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Median PS Value Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Price-to-Median-PS-Value vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 1.3059.
Orion Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT16.065.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a Median PS Value of BDT20.98 as of Jul. 13, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Orion Pharma and its competitors. This is 1565% above median its historical median of 1.26. Over the past decade, Orion Pharma's Median PS Value has ranged from 0.87 to 2.22. According to the industry distribution chart, Orion Pharma ranks #149 out of 195 companies in the Utilities - Independent Power Producers industry, placing it in the top 76.4%.
Is Orion Pharma's Median PS Value too high?
Orion Pharma's current Median PS Value of BDT20.98 is 1565% above median its 10-year median of 1.26. Over the past 10 years, this metric has ranged from a low of 0.87 to a high of 2.22. Based on the distribution chart, Orion Pharma ranks #149 out of 195 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Median PS Value compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #149 out of 195 companies for Median PS Value. This places Orion Pharma in the lower half of its industry. The industry median Median PS Value is 1.01. Historically, Orion Pharma's own Median PS Value has ranged from 0.87 to 2.22 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for an Utilities - Independent Power Producers company?
The median Median PS Value among Utilities - Independent Power Producers companies is 1.01, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Median PS Value is 1.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Median PS Value is BDT20.98, which is 1565% above median its own 10-year median of 1.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.18, compared to a current price of BDT30.10 — trading 49.2% above its estimated fair value. The current Median PS Value is BDT20.98, which is 1565% above median its 10-year median of 1.26. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Median PS Value is BDT20.98 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT30.10 is trading 49.2% above its estimated GF Value™ of BDT20.18.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Median PS Value: BDT20.98 (1565% above median its 10-year median of 1.26)
GF Value™: BDT20.18 vs. price of BDT30.10 (49.2% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score
Get the complete analysis for DHA:ORIONPHARM
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
